IMRXBiotechnology / BiotechnologyMulti-year analysis
Immuneering Corp— Fundamentals deep dive
Five-year ratio trends, valuation spread across DCF / EPV / EV-revenue, quality scores, statement history, and peer positioning forIMRX. A companion to the IMRXsnapshot.
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Statement history
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $316,952 | $-52M | $-51M | $-45M |
| 2023-12-31 | $0 | $-58M | $-53M | $-49M |
| 2024-12-31 | $0 | $-64M | $-61M | $-55M |
| 2025-12-31 | $0 | $-59M | $-56M | $-45M |
After signup
Open the full statement deep-dive
Extend history beyond this four-year public window into longer cycles.
Drill from summary lines into working capital, debt, capex, and cash-flow detail.
Cross-link statement changes with alerts and saved workflows.
Ready to run your own scenarios onIMRX?
Tune DCF assumptions, compare against custom peer sets, layer in conviction and regime context, and save the thesis to your watchlist.
For informational and educational purposes only. Not financial advice. Learn more